According to Dr Puja Sharma, mutations in BRCA1/2 or acquired DNA damage drive malignant breast cell proliferation. Early indicators include nipple retraction and bloody discharge. Clinical Breast Examination and mammography remain vital diagnostic tools. Molecular receptor testing informs systemic therapy, while advances in immunotherapy improve outcomes.